Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity‐associated cytokine, osteopontin
Authors:
Open Access
- 7 May 2009
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 265 (6) , 632-643
Abstract
: Intracellular signalling emanating from the B‐cell antigen receptor is considered to follow a discrete course that requires participation by a set of mediators, grouped together as the signalosome, in order for downstream events to occur. Recent work indicates that this paradigm is true only for naïve B cells. Following engagement of the IL‐4 receptor, a new, alternate pathway for B‐cell receptor (BCR)‐triggered intracellular signalling is established that bypasses the need for signalosome elements and operates in parallel with the classical, signalosome‐dependent pathway. Reliance on Lyn and sensitivity to rottlerin by the former, but not the latter, distinguishes these two pathways. The advent of alternate pathway signalling leads to production and secretion by B cells of osteopontin (Opn). As Opn is a polyclonal B‐cell activator that is strongly associated with a number of autoimmune diseases including lupus and rheumatoid arthritis, this novel finding is likely to be clinically relevant. Our results highlight the potential role of B‐cell‐derived Opn in immunity and autoimmunity and suggest that stress‐related IL‐4 expression might act to strengthen immunoglobulin secretion at the risk of autoantibody formation. Further, these results illustrate receptor crosstalk in the form of reprogramming, whereby engagement of one receptor (IL‐4R) produces an effect that persists after the original ligand (IL‐4) is removed and results in alteration of the pathway, and outcome, of signalling via a second receptor (BCR) following its activation.Keywords
This publication has 104 references indexed in Scilit:
- Aberrant T cell ERK pathway signaling and chromatin structure in lupusAutoimmunity Reviews, 2009
- B cell receptor crosstalk: B cells express osteopontin through the combined action of the alternate and classical BCR signaling pathwaysMolecular Immunology, 2008
- The potential utility of B cell-directed biologic therapy in autoimmune diseasesRheumatology International, 2007
- PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signalingNature Immunology, 2002
- Differential roles of osteopontin/Eta-1 in early and late lpr diseaseClinical and Experimental Immunology, 2001
- Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor EngagementJournal of Experimental Medicine, 2000
- Bruton's Tyrosine Kinase Links the B Cell Receptor to Nuclear Factor κb ActivationJournal of Experimental Medicine, 2000
- Tear levels of interferon‐γ, interleukin (IL) ‐2, IL‐4 and IL‐5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitisClinical & Experimental Allergy, 2000
- Defective B cell development and function in Btk-deficient miceImmunity, 1995
- Rottlerin, a Novel Protein Kinase InhibitorBiochemical and Biophysical Research Communications, 1994